The neurotoxicity of tunicamycin

Related Experiment Videos

D D Leaver1, K M Schneider, M J Rand

  • 1Department of Pharmacology, University of Melbourne, Victoria, Australia.

Toxicology
|April 1, 1988
PubMed

Insights

Tunicamycin, a glycosylation inhibitor, causes neurotoxicity in rats by damaging brain cells and blood vessels. This study suggests its primary target is the endothelial cells within brain microvessels.

Area of Science:

  • Neuroscience
  • Toxicology
  • Vascular Biology

Background:

  • Tunicamycin inhibits glycoprotein glycosylation and is explored as an anti-tumour agent.
  • Neurotoxicity is a potential side effect requiring investigation.
  • Understanding tunicamycin's mechanism of action is crucial for its therapeutic development.

Purpose of the Study:

  • To investigate the neurotoxic effects of tunicamycin.
  • To elucidate the mechanism underlying tunicamycin-induced neurotoxicity.
  • To identify the primary cellular targets of tunicamycin in the brain.

Main Methods:

  • Direct injection of tunicamycin into the lateral ventricle of rat brains.
  • Histopathological examination of brain tissue to identify lesions.
  • In vitro study using rabbit aortic rings to assess vascular effects.

Main Results:

  • Tunicamycin induced a delayed neurological syndrome characterized by anoxic necrosis and white matter degeneration.
  • Brain lesions exhibited features consistent with infarcts, indicating vascular damage.
  • In vitro, tunicamycin progressively inhibited the acetylcholine-induced relaxation response in aortic rings, dependent on endothelium-derived relaxing factor.

Conclusions:

  • Tunicamycin causes significant neurotoxicity in rats, leading to brain cell death and vascular damage.
  • The vascular effects observed in vivo and in vitro suggest a primary impact on endothelial cells.
  • Endothelial cells of brain microvessels are proposed as the critical target in tunicamycin neurotoxicity.

Related Concept Videos